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Abstract
Background: Trichostatin A (TSA), a potent inhibitor of histone deacetylases exhibits strong anti-tumor and growth
inhibitory activities, but its mechanism(s) of action is not completely understood. Osteopontin (OPN) is a secreted
glycoprotein which has long been associated with tumor metastasis. Elevated OPN expression in various metastatic
cancer cells and the surrounding stromal cells often correlates with enhanced tumor formation and metastasis. To
investigate the effects of TSA on OPN transcription, we analyzed a proximal segment of OPN promoter in cervical
carcinoma cells.
Results: In this paper, we for the first time report that TSA suppresses PMA-induced OPN gene expression in
human cervical carcinoma cells and previously unidentified AP-1 transcription factor is involved in this event.
Deletion and mutagenesis analyses of OPN promoter led to the characterization of a proximal sequence (-127 to
-70) that contain AP-1 binding site. This was further confirmed by gel shift and chromatin immunoprecipitation
(ChIP) assays. Western blot and reverse transcription-PCR analyses revealed that TSA suppresses c-jun recruitment
to the OPN promoter by inhibiting c-jun levels while c-fos expression was unaffected. Silencing HDAC1 followed
by stimulation with PMA resulted in significant decrease in OPN promoter activity suggesting that HDAC1 but not
HDAC3 or HDAC4 was required for AP-1-mediated OPN transcription. TSA reduces the PMA-induced
hyperacetylation of histones H3 and H4 and recruitment of RNA pol II and TFIIB, components of preinitiation
complex to the OPN promoter. The PMA-induced expression of other AP-1 regulated genes like cyclin D1 and uPA
was also altered by TSA. Interestingly, PMA promoted cervical tumor growth in mice xenograft model was
significantly suppressed by TSA.
Conclusions: In conclusion, these findings provide new insights into mechanisms underlying anticancer activity of
TSA and blocking OPN expression at transcriptional level by TSA may act as novel therapeutic strategy for the
management of cervical cancer.
Background
Osteopontin (OPN) is a secreted, noncollagenous, sialic
acid-rich, cytokine-like glycosylated phosphoprotein
which is a member of Small Integrin Binding LIgand
N-linked Glycoprotein (SIBLING) family and plays
important role in determining the oncogenic potential
of various cancers [1,2]. OPN expression is increased in
a variety of cancers and is reported to correlate with
enhanced tumor progression and metastasis [3-5]. OPN
plays crucial roles in cancer cell metastasis, granuloma
formation, dystrophic calcification and in coronary rest-
enosis [6-11]. The prometastatic effects of OPN like cell
adhesion, ECM invasion and cell proliferation are exhib-
ited through interaction with its receptors which regu-
lates various cell signaling pathways ultimately leading
to tumor progression [12]. Earlier reports have shown
that tumor-derived OPN is soluble and has close simi-
larity with human milk OPN [13,14]. OPN is also found
intracellularly, associated with ezrin and the cytoplasmic
domain of CD44. It is important in transducing signals
that leads to cytoskeletal rearrangements required dur-
ing cell migration, fusion and bone resorption [1,15].
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The expression of the genetic information encoded in
the DNA is regulated largely by the chromatin structure
[16]. Nucleosomes are the repeating units in chromatin
which are composed of an octamer core of pairs of his-
tones H2A, H2B, H3 and H4 wrapped with two super-
helical turns of DNA around it [17]. Posttranslational
covalent modifications of histones like acetylation and
methylation of lysines and arginines and phosphoryla-
tion of serines have been shown to be important in gene
regulation [18,19]. Acetylation of histones leads to neu-
tralization of the positive charge of lysine residues,
resulting in altered chromatin conformation. In this
case, promoter regions of genes may be more accessible
to transcription factor complexes [20].
The extent of histone acetylation is determined by the
activities of the enzymes histone deacetylases (HDACs)
and histone acetyltransferases (HATs) [21-24]. HAT or
HDAC activity has been found to be disrupted in many
cancers [25-29]. HDAC activity is increased in cancer
cells and has been linked to carcinogenesis [30]. Various
chemically and structurally diverse agents have been dis-
covered which specifically inhibit HDAC activity. These
include first natural product hydroxamate trichostatin A
(TSA), suberoylanilide hydroxamic acid (SAHA), alipha-
tic compound valproic acid and several other natural
and synthetic derivatives [31,32]. HDAC inhibitors exhi-
bit growth inhibitory and anti-tumor activities like cell
cycle arrest, inhibition of cell proliferation and induction
of apoptosis in cancer cells both in vitro and tumor-
bearing animals [33,34]. A number of HDAC inhibitors
have been shown to be effective in phase I/II clinical
trials. However, the mechanisms by which HDAC inhi-
bitors regulate gene expression and show anti-tumor
activities are not completely understood and remain to
be elucidated [35].
In the present study, we have examined the effect of
HDAC inhibitor, TSA on OPN transcription using
human cervical carcinoma as a model. We found that
TSA inhibits PMA-induced OPN gene expression. TSA
suppressed the PMA-induced c-Jun recruitment to the
OPN promoter by inhibiting c-Jun expression both at
protein and RNA levels. Our results also identified the
previously unrecognized AP-1 binding site in the human
OPN promoter which is functionally active. We have
also observed that TSA not only suppresses OPN tran-
scription but also inhibits the expression of other AP-1
regulated genes like cyclin D1 and uPA. TSA suppresses
the PMA-regulated tumor growth in mice xenograft
model. In summary, these results suggest that HDAC
inhibitor, TSA suppresses PMA-induced c-Jun expres-
sion leading to downregulation of AP-1 regulated genes
like OPN, cyclin D1 and uPA. This data revealed that
inhibiting OPN transcription by TSA might be an
important therapeutic approach for the control of cervi-
cal cancer.
Materials and methods
Cell culture, antibodies and other reagents
The human cervical carcinoma cell lines, HeLa and SiHa
were cultured in Minimum Essential Medium Eagle sup-
plemented with 10% fetal bovine serum, 100 units/ml
penicillin, 100 μg/ml streptomycin and 2 mM glutamine.
The cells were maintained in a humidified atmosphere
of 5% CO2 and 95% air at 37°C. The anti-OPN antibody
was obtained from Chemicon International. The anti-
HDAC4, anti-c-Jun, anti-c-Fos, anti-acetyl-H3, anti-
acetyl-H4, anti-RNA pol II, anti-TFIIB, anti-cyclin D1,
anti-uPA, anti-OPN and anti-actin antibodies were pur-
chased from Santa Cruz Biotechnology. The anti-
HDAC1 and anti-HDAC3 antibodies were from Upstate
Biotechnology. PMA was purchased from Sigma. Tri-
chostatin A (TSA) was obtained from Cell Signaling
Technology. TSA was dissolved in minimum volume of
ethanol, further diluted with media and used for in vitro
and in vivo studies.
Western blot analysis
HeLa cells were pretreated with TSA (0-1 μM) and then
treated with PMA (50 ng/ml). In separate experiments,
SiHa cells were treated with TSA (0-2 μM). Cells were
lysed in lysis buffer and the lysates containing equal
amount of total proteins (30-50 μg) were resolved by
SDS-PAGE and blotted onto nitrocellulose membranes.
The levels of OPN, c-Jun, c-Fos, cyclin D1 and uPA were
analyzed by western blot using their specific antibodies.
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed as described previously [36].
HeLa cells were treated with PMA (50 ng/ml), nuclear
extracts (5 μg each) were incubated with g-32P-labeled
double-stranded oligonucleotide containing the AP-1
binding site of OPN promoter in binding buffer (25 mM
HEPES (pH 7.9), 0.5 mM EDTA, 0.5 mM DTT, 1%
Nonidet P-40, 5% glycerol, and 50 mM NaCl) containing
2 μg of polydeoxyinosinic deoxycytidylic acid (poly dI-
dC). The sequence of the probe used was 5′ AAC CTC
ATG ACA CAA TCT CTC 3′. The DNA-protein com-
plex was resolved on 8% native polyacrylamide gel and
analyzed by autoradiography. For supershift assay, the
PMA-treated nuclear extracts were incubated with
either anti-c-Jun or anti-c-Fos antibody and then EMSA
was performed.
RNA isolation and reverse transcription-PCR
RNA isolation and reverse transcription-PCR were per-
formed as mentioned earlier [37]. Briefly, HeLa cells
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were pretreated with TSA (0-1 μM) followed by treat-
ment with PMA (50 ng/ml). In separate experiments,
SiHa cells were treated with TSA (0-2 μM). Total RNA
was extracted using Trizol reagent (GIBCO BRL, Grand
Island, NY) and reverse transcription-PCR was per-
formed using following sets of primers. OPN (forward 5′
AGA CCT GAC ATC CAG TAC CCT G 3′, reverse 5′
GTG GGT TTC AGC ACT CTG GT 3′), c-jun (forward
5′ ATG GAG TCC CAG GAG CGG ATC AA 3′,
reverse 5′ GTT TGC AAC TGC TGC GTT AG 3′), c-
fos (forward 5′ AAC CGG AGG AGG GAG CTG ACT
GAT 3′ reverse 5′ GGG CCT GGA TGA TGC TGG
GAA CA 3′), cyclin D1 (forward 5′ CTT CCT CTC
CAA AAT GCC AG 3′, reverse 5′ AGA GAT GGA
AGG GGG AAA GA 3′), uPA (forward 5′ CAC GCA
AGG GGA GAT GAA 3′, reverse 5′ ACA GCA TTT
TGG TGG TGA CTT 3′) and actin (forward 5′ GGC
ATC CTC ACC CTG AAG TA 3′, reverse 5′ GGG
GTG TTG AAG GTC TCA AA 3′). Aliquots of PCR
products were analyzed by electrophoresis using 1.2%
agarose gel.
Chromatin immunoprecipitation (ChIP) assay
This assay was performed with ChIP assay kit (Upstate
Biotechnology, Temecula, CA) according to the manufac-
turer’s instructions. Briefly, cells were cross-linked in 1%
formaldehyde solution for 10 min at room temperature.
Cells were lysed in 300 μl of SDS lysis buffer and soni-
cated to generate 200-1000 bp DNA fragments. The
cross-linked chromatin in sonicated fractions were
immunoprecipitated with anti-p-c-Jun, anti-acetyl H3,
anti-acetyl H4, anti-RNA pol II or anti-TFIIB antibody.
DNA fragments were analyzed by PCR using specific pri-
mers which include AP-1 binding site of OPN promoter
(forward 5′-TCT TCC TGG ATG CTG AAT GC-3′,
reverse 5′-CCA AGC CCT CCC AGA ATT TAA-3′).
Construction of expression vectors and site directed
mutagenesis
The human OPN promoter fragments (-500/+20, -267/
+20, -127/+20) cloned in pGL3 vector were generous
gift from Dr. J. H. Chen (Tzu Chi University, Taiwan).
Two deletion constructs of the promoter, -70/+20 and
-20/+20 were generated by PCR with two 5′ primers
and a fixed 3′ primer. The PCR amplified fragments
were digested with Kpn I and Sac I and further cloned
into promoter-less luciferase reporter plasmid pGL3-
Basic (Promega, Medison, WI). Three mutation con-
structs namely CM, AM and OM were generated using
QuickChange site-directed mutagenesis kit according to
the manufacturer’s instructions (Stratagene, La Jolla,
CA) in which binding sites of CEBPa/AML-1, AP-1 and
Oct-1/Oct-2 transcription factors are respectively
mutated.
Transfection and luciferase reporter assay
HeLa cells were seeded in 12-well plates and transfected
with 2 μg of human OPN promoter deletion and muta-
tion constructs using 4 μl of Lipofectamine 2000 as per
the manufacturer’s instructions. After 6 h of incubation,
the medium was replaced with complete medium. The
luciferase activity was measured in cell lysates using
dual luciferase reporter assay kit from Promega and nor-
malized to Renilla luciferase activity. Fold-changes in
luciferase activity with respect to control were
calculated.
RNA interference
Cells were transiently transfected with HDAC1, HDAC3
(siRNA kit from Upstate Biotechnology, Temecula, CA)
and HDAC4 (Santa Cruz Biotechnology, Santa Cruz,
CA) specific siRNA using Lipofectamine 2000 according
to the manufacturer’s instructions. These siRNA trans-
fected cells were used for reporter assay and western
blot analysis.
In vivo tumorigenicity, histopathology and
immunofluorescence
The tumorigenicity and immunofluorescence experi-
ments were performed as described [38]. Briefly, HeLa
cells (1 × 106/0.2 ml) were mixed with matrigel (1:1
ratio, BD Biosciences) and injected subcutaneously into
the flanks of female NOD/SCID mice (6-8 weeks old).
The mice were maintained under specific pathogen-free
conditions according to the guidelines of Experimental
Animal Facility (EAF) of National Centre for Cell
Science. Six mice were used in each group of animals.
PMA (10 μg/kg body weight) was injected intratumo-
rally. In some experiments, two doses of TSA (0.5 mg/kg
and 4 mg/kg body weight) along with PMA were injected
to the site of the tumors. Tumor volume was estimated
using the following formula: π/6 [(d1 × d2)3/2], where d1
and d2 are the two perpendicular diameters. Mice were
sacrificed after 4 weeks and tumors were excised. The
tumors were immediately snap-frozen in liquid nitrogen
and the levels of OPN, c-Jun, uPA and cyclin D1 in the
tumor lysates were analyzed by western blotting and
reverse transcription-PCR. The remaining portions of
the tumor samples were formalin fixed and tumor sec-
tions were analyzed by immunofluorescence using their
specific antibodies.
Statistical analysis
The results of luciferase reporter and tumorigenicity
assay are expressed as mean ± SD and ± SEM respec-
tively. Statistical differences were analyzed by Student’s
t test. A P value of < 0.05 was considered as significant.
All bands were analyzed densitometrically and the fold
changes were calculated (Kodak Digital Science).
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Results
TSA suppresses PMA-induced OPN transcription in HeLa
cells
Earlier reports have shown that stimulation of smooth
muscle cells with PMA results in induction of OPN gene
expression [11]. To determine whether HDAC inhibitor,
TSA could suppress PMA-induced OPN expression,
HeLa cells were pretreated with TSA (0-1 μM) for 1 h
before being treated with PMA. Expression of OPN both
at protein and mRNA levels was analyzed by western blot
and reverse transcription-PCR respectively. It was
observed that treatment of cells with TSA resulted in
decrease in PMA-induced OPN expression in a dose
dependent manner. The results showed that TSA was
able to inhibit OPN expression both at protein (Figure
1A) as well as mRNA (Figure 1B) levels. To investigate
whether TSA regulates OPN expression in other cervical
cancer cells, highly invasive SiHa cells were treated with
TSA. The data revealed that TSA suppresses OPN tran-
scription at protein and mRNA levels in these cells also
(Additional file 1, Figure S1A and Figure S1B).
Deletion and mutagenesis analyses of OPN promoter
The proximal segment of human OPN promoter and its
sequence containing various transcription factor binding
sites are shown (Additional file 2, Figure S2A and Figure
S2B). To characterize the regulatory sequence involved in
PMA-induced activation of OPN transcription, a proximal
segment (-500 to +20 region) in the human OPN promo-
ter containing C/EBPa/AML-1, AP-1 and Oct-1/Oct-2
transcription factor binding sites was taken into considera-
tion. A region from -500 to +20 of the hOPN promoter
Figure 1 TSA suppresses PMA-induced OPN transcription in HeLa cells. A. HeLa cells were preincubated with 0-1 μM TSA for 1 h followed
by treatment with PMA (50 ng/ml) for 6 h. Whole cell lysates were analyzed by western blot using anti-OPN antibody. B. HeLa cells were
pretreated with TSA followed by PMA under similar conditions as described above. Total RNA was isolated and OPN mRNA levels were detected
by semiquantitative RT-PCR and analyzed by agarose gel electrophoresis. Actin was used as control. The data represents three experiments
exhibiting similar results. C. HeLa cells were cotransfected with hOPN promoter deletion constructs (-500/+20, -267/+20, -127/+20, -70/+20 and
-20/+20) containing luciferase reporter gene along with renilla luciferase vector, pRL followed by stimulation with PMA. The luciferase activity
was measured in cell lysates and normalized to Renilla luciferase activity. Fold-changes in luciferase activity with respect to control were
calculated. Columns, mean of triplicate determinations; bar, S.D. *, p < 0.05. D. HeLa cells were cotransfected with various hOPN promoter
mutation constructs (-500/+20, CM, AM and OM) containing luciferase gene along with pRL vector and treated with PMA. The luciferase activity
was measured and normalized. Fold-changes in luciferase activity with respect to control were calculated. Columns, mean of triplicate
determinations; bar, S.D. *, p < 0.05.
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sequence and serially deleted promoter sequences (-267/
+20, -127/+20, -70/+20 and -20/+20) were cloned into
promoter-less luciferase reporter plasmid, pGL3-Basic.
The luciferase activity was analyzed in HeLa cells cotrans-
fected with OPN promoter constructs along with Renilla.
When luciferase activities of transfected cells were assayed,
deletion of the region between -127 and -70 resulted in a
dramatic decrease in OPN promoter activity suggesting
that AP-1 binding site located in this region might be
responsible for OPN transcription in response to PMA
(Figure 1C). To further confirm the role of AP-1 binding
sequence in PMA-induced OPN expression, mutation
constructs were generated, namely CM, AM and OM in
which C/EBPa/AML-1, AP-1 and Oct-1/Oct-2 binding
sites were respectively mutated. Mutations within the AP-
1 binding sequence caused significant reduction in the
promoter activity upon PMA treatment (Figure 1D) sug-
gesting the involvement of AP-1 in PMA-induced OPN
transcription.
Identification of transcription factor involved in
PMA-induced OPN expression
The transcription factor binding to the OPN promo-
ter in response to PMA was identified by electro-
phoretic mobility shift assay. The nuclear extract pre-
pared from HeLa cells was incubated with labeled oli-
gonucleotide probe containing AP-1 binding sequence
of OPN promoter. A specific complex was detected in
the nuclear extracts of PMA-treated HeLa cells and
the unlabeled oligonucleotide could competitively
inhibit the complex formation (Figure 2A) indicating
the specificity of the DNA-protein interaction. Super-
shift assay was performed to investigate whether c-
Jun or c-Fos could bind to the sequence in the probe
using their specific antibodies. Addition of either of
the antibody resulted in supershift indicating the pre-
sence of AP-1 heterodimer at the OPN promoter in
response to PMA (Figure 2B). To confirm the in vivo
recruitment of c-Jun to the OPN promoter, ChIP
assay was performed. This assay reflects the binding
of the protein to the endogenous gene. Cross-linked
chromatin was immunoprecipitated using anti-p-c-Jun
antibody, the reverse cross-linked DNA was PCR
amplified using a set of primers containing AP-1
binding site of OPN promoter. The results showed
the induction of recruitment of c-Jun to the OPN
promoter upon PMA treatment which was inhibited
by TSA (Figure 2C).
Figure 2 PMA induces AP-1 DNA binding to the OPN promoter in HeLa cells. A. HeLa cells were treated with PMA (50 ng/ml) for 2 h.
Nuclear extracts were prepared and incubated with 32P-labeled probe containing AP-1 binding site of OPN promoter and analyzed by EMSA. B.
For supershift assay, nuclear extracts from PMA-treated HeLa cells were incubated with anti-c-Jun or anti-c-Fos antibody and then analyzed by
EMSA. C. HeLa cells were pretreated with TSA (0.5 μM) for 1 h and then with PMA (50 ng/ml) for 2 h. Cross-linked chromatin fragments were
immunoprecipitated with anti-p-c-Jun antibody and was PCR amplified using specific primers derived from the region of OPN promoter
containing AP-1 binding site. For negative controls, normal mouse IgG was used or specific antibody was omitted.
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TSA suppresses PMA-induced c-Jun but not c-Fos
expression
One of the mechanisms by which recruitment of c-Jun
to the OPN promoter could be affected is by alteration
in its expression. To examine this hypothesis, c-Jun
expression both at RNA and protein levels was detected
in lysates of HeLa cells preincubated with TSA followed
by treatment with PMA. The results showed that TSA
suppresses PMA-induced c-Jun expression at protein
(Figure 3A) as well as mRNA (Figure 3B) levels. In con-
trast, TSA did not have any effect on c-Fos expression
(Figure 3C and Figure 3D) suggesting that the recruit-
ment of c-Jun but not c-Fos is regulated by TSA. To
further investigate whether this phenomenon is applic-
able to other cervical cancer cells, highly invasive SiHa
cells were treated with TSA and the levels of c-Jun and
c-Fos were analyzed. The data revealed that TSA sup-
presses c-Jun but not c-Fos expression both at protein
and mRNA levels (Additional file 3, Figure S3 A-D).
Determination of acetylation status of histones H3 and
H4 in response to PMA and TSA
Previous studies have demonstrated that HDAC inhibi-
tors induce the accumulation of acetylated histones in
both transformed and normal cells [39-41]. To
investigate whether treatment of cells with PMA and
TSA has any effect on the pattern of acetylation of his-
tones associated with OPN promoter, we performed
chromatin immunoprecipitation assays using anti-acetyl
H3 and anti-acetyl H4 antibodies and primers contain-
ing the AP-1 binding site of OPN promoter. We found
that exposure of cells with PMA led to hyperacetylation
of histones H3 and H4 in the proximal region of OPN
promoter. This PMA-induced hyperacetylation of his-
tones was inhibited by TSA in a dose dependent manner
(Figure 4A and Figure 4B).
PMA enhances the recruitment of RNA pol II and TFIIB to
OPN promoter, an effect that is reversed by TSA
Previous reports have shown that HDAC inhibitors
interfere with the initiation of transcription by block-
ing the recruitment of components of pre-initiation
complex [42]. Therefore, we next examined whether
PMA and TSA have any effect on the association of
RNA polymerase II and TFIIB with OPN promoter
sequence having AP-1 binding site. Employing ChIP
assays, we observed that stimulation of HeLa cells with
PMA caused induction in the binding of RNA pol II
and TFIIB to AP-1 binding region of OPN promoter.
The results also revealed that TSA was able to
Figure 3 TSA blocks PMA-induced c-Jun but not c-Fos expression in HeLa cells. A and C. HeLa cells were pretreated with TSA (0-1 μM) for
1 h followed by treatment with PMA (50 ng/ml) for 2 h. Cell lysates (50 μg) containing equal amount of total proteins were analyzed by western
blot using either anti-c-Jun or anti-c-Fos antibody. B and D. HeLa cells were pretreated with TSA and then with PMA under similar conditions as
described above. Total RNA was isolated and the levels of c-jun and c-fos mRNAs were detected by semiquantitative RT-PCR. Actin was used as
control.
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Figure 4 TSA inhibits PMA-induced hyperacetylation of histones H3 and H4 and recruitment of RNA pol II and TFIIB to OPN promoter
in HeLa cells. A-D. HeLa cells were pretreated with TSA for 1 h and then with PMA for 2 h. Cross-linked DNA-protein complexes were
immunoprecipitated with anti-acetyl H3, anti-acetyl H4, anti-RNA pol II or anti-TFIIB antibody and PCR amplified using specific primers derived
from the region of OPN promoter containing AP-1 binding site. For negative controls, normal mouse IgG was used. The data represents three
experiments exhibiting similar results.
Figure 5 HDAC1 is involved in regulation of PMA-induced OPN promoter activity in HeLa cells. A. panels I-III. HeLa cells were
transfected with either siRNAs to HDAC1, HDAC3 and HDAC4 or control siRNA. The expressions of various HDACs were analyzed by western
blot using their specific antibodies. Actin served as loading control. B. HeLa cells were transfected with siRNAs to HDAC1, HDAC3 and HDAC4.
These transfected cells were cotransfected with hOPN promoter (-500/+20) containing luciferase reporter gene along with Renilla luciferase, pRL
vector and then treated with PMA. The luciferase activity was measured in cell lysates and normalized to Renilla luciferase activity. Fold-changes
in luciferase activity with respect to control were calculated. Columns, mean of triplicate determinations; bar, S.D. *, p < 0.05.
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abrogate the PMA-induced RNA pol II and TFIIB
association with OPN promoter (Figure 4C and Figure
4D) in a similar manner as observed in the case of his-
tones H3 and H4. These findings suggest that TSA
altered the recruitment of components of basal tran-
scription machinery.
Silencing HDAC1 expression leads to decrease in
PMA-induced OPN promoter activity
TSA inhibits various histone deacetylases and exhibits lit-
tle or no preference for HDACs [23,43]. Therefore, it is of
great interest to characterize the class of HDAC involved
in OPN transcription in response to PMA. The expres-
sions of HDACs in lysates of siRNA transfected cells were
analyzed by western blot to check the specificity of the
siRNAs (Figure 5, panel A, I-III). The luciferase assay
showed that HDAC1 siRNA but not HDAC3 or HDAC4
siRNA significantly decreased the PMA-induced OPN
promoter activity (Figure 5, panel B) suggesting that
HDAC1 is involved in PMA-induced OPN transcription.
Expression of AP-1 regulated genes in response to PMA
and TSA
Our previous results have shown that TSA inhibits c-
Jun expression and thereby it suppresses PMA-induced
OPN transcription. To investigate whether TSA altered
the expression of two well known AP-1 regulated genes
such as cyclin D1 and uPA, HeLa cells were pretreated
with TSA and then with PMA and levels of cyclin D1
and uPA were analyzed by western blot and reverse
transcription-PCR. The data revealed that TSA sup-
pressed PMA-induced expression of both cyclin D1
(Figure 6A and Figure 6B) and uPA (Figure 6C and Fig-
ure 6D) in dose dependent manner both at protein and
mRNA levels respectively.
TSA suppresses cervical tumor growth in response to
PMA in NOD/SCID mice xenograft model
Our in vitro data further prompted us to extend this
study to in vivo mice models. Therefore, to examine
whether PMA promotes the cervical tumor growth and
TSA plays any role in regulation of this process, HeLa
cells were injected subcutaneously into the NOD/SCID
mice. Either PMA alone or in combination with two
doses of TSA was injected intratumorally. After 4
weeks, mice were sacrificed and tumors were excised.
The tumor volumes were calculated and the growth
kinetics of tumor volume in fold change vs time in
weeks is represented in the form of graph (Figure 7A).
The error bars represent the standard error of mean.
Figure 6 Effect of TSA on cyclin D1 and uPA expression at protein and RNA levels in HeLa cells. A and C. HeLa cells were pretreated
with TSA (0-1 μM) for 1 h followed by treatment with PMA (50 ng/ml) for 6 h. Cell lysates were analyzed by western blot using anti-cyclin D1 or
anti-uPA antibody. B and D. Total RNA was isolated from HeLa cells treated under similar conditions and cyclin D1 and uPA mRNA levels were
detected by semi-quantitative RT-PCR. Actin was used as loading control for both western blot and RT-PCR.
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The data revealed that PMA promoted tumor growth
was significantly suppressed by TSA. The tumor lysates
were analyzed for the expressions of OPN, c-Jun, cyclin
D1 and uPA by western blot and RT-PCR (Figure 7B
and Figure 7C). Higher expressions of these oncogenic
proteins were observed in the lysates of tumors obtained
from mice treated with PMA alone as compared to mice
in the control group. These levels were substantially
reduced in the lysates of tumors obtained from mice
treated with two doses of TSA along with PMA
(Figure 7B and Figure 7C). The typical tumor photo-
graphs are shown in Additional file 4, Figure S4A. The
western blot and RT-PCR data were further confirmed
by immunofluorescence analysis. The tumor samples
were analyzed by immunofluorescence using anti-OPN,
anti-c-Jun, anti-cyclin D1 and anti-uPA antibodies. The
data revealed that the expression of these molecules was
higher in tumors generated by PMA and TSA sup-
presses their expressions (Additional file 4, Figure S4B).
This data demonstrates that OPN, c-Jun, cyclin D1 and
uPA play crucial role in PMA-induced cervical tumor
growth in NOD/SCID mice while TSA exerts its anti-
tumor effects by downregulation of these oncogenic
molecules.
Discussion
HDAC inhibitors have emerged as promising chemother-
apeutic agents. Previous studies have demonstrated that
these inhibitors exhibit a range of anti-tumor activities
including cancer cell cycle arrest, stimulation of differen-
tiation and induction of apoptosis [35]. However, the
mechanisms by which HDAC inhibitors show their antic-
ancer activities are not completely understood and
remain to be elucidated [44]. Earlier reports have shown
Figure 7 TSA suppresses cervical tumor growth in response to PMA in NOD/SCID mice model. A. HeLa cells (1 × 106/0.2 ml) were mixed
with matrigel (1:1 ratio) and injected subcutaneously into the flanks of mice. Six mice were kept in each group. Either PMA alone or in
combination with two doses of TSA was injected intratumorally. After 4 weeks, mice were sacrificed and tumors were excised. The tumor
volumes were calculated and the growth kinetics in tumor volume in fold change vs time in weeks is represented in the form of graph. The
error bars represent the standard error of mean (SEM). *, p < 0.05. B and C. Tumor lysates were analyzed by western blot using anti-OPN, anti-c-
Jun, anti-cyclin D1 and anti-uPA antibodies. Tumors were also analyzed by semiquantitative RT-PCR using gene specific primers. Actin was used
as control. D. Schematic representation of PMA-induced OPN transcription through c-Jun leading to enhanced cervical tumor growth and TSA
suppresses this process.
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that these inhibitors can have effect on gene expression,
induce accumulation of acetylated histones and enhance
protein degradation, all of which can contribute to the
anti-proliferative effects [33,45,46]. A possible mechan-
ism by which these inhibitors control cancer cell growth
is through downregulation of expression of proteins
involved in proliferation and metastasis. One such pro-
tein is OPN, elevated levels of which have been linked to
enhanced metastatic phenotype. To examine this hypoth-
esis, we investigated the effect of TSA on PMA-induced
OPN transcription. In this study, we observed that TSA
suppresses OPN transcription in a dose dependent man-
ner both at protein and mRNA levels.
Human OPN promoter deletion and mutagenesis
analyses led to the characterization of AP-1 transcrip-
tion factor being involved in regulation of OPN tran-
scription in response to PMA. Its role in this
phenomenon was further confirmed by performing
electrophoretic mobility shift assay (EMSA). Supershift
assay revealed the presence of c-jun/c-fos heterodimer
at the OPN promoter. The in vivo recruitment of c-jun
to the OPN promoter was established by chromatin
immunoprecipitation assay. TSA was observed to inhi-
bit this recruitment. Moreover, Sakata et al have
demonstrated that TSA activates the OPN gene pro-
moter through AP-1 site in mouse undifferentiated
mesenchymal cell line [47]. We addressed the question
how the recruitment of c-jun to the OPN promoter
was affected by TSA in cervical cancer cells. One pos-
sible mechanism could be by changing the c-jun
expression. To validate this hypothesis, c-jun expres-
sion was analyzed by western blot as well as by
RT-PCR. Interestingly, the data revealed that TSA
inhibited c-jun transcription affecting both protein and
mRNA levels which leads to the reduction in c-jun
binding to the OPN promoter. To our surprise, c-fos
levels were unchanged by PMA and TSA treatment.
We also investigated the acetylation status of histones
H3 and H4 associated with the AP-1 binding sequence
of OPN promoter. Employing ChIP assays, we
observed that TSA inhibits the hyperacetylation of his-
tones H3 and H4 which is induced by PMA. This
could be one of the mechanisms by which OPN
expression is suppressed by TSA since acetylation sta-
tus of the histones is directly correlated with gene
expression. This report also showed that TSA can
block the recruitment of components of the preinitia-
tion complex viz RNA polymerase II and TFIIB to the
OPN promoter. These findings were consistent with
previous evidence that HDAC activity is required to
recruit the preinitiation complex to selected genes that
are activated by the transcription factors Stat 1, Stat 2
and Stat 5 [48,49].
Histone deacetylases have been divided into different
classes. HDAC1, but not HDAC3 and HDAC4 seemed
to be required for OPN transcription in response to
PMA as determined by siRNA transfection experiments.
OPN promoter activity was significantly reduced upon
silencing HDAC1 suggesting its importance in the regu-
lation of OPN expression by PMA. Since it was
observed that TSA inhibits the PMA-induced OPN tran-
scription by altering the expression of c-jun, we sought
to determine whether TSA has any effect in regulation
of expression of other c-jun specific target genes.
Indeed, the expression of two well-known AP-1 regu-
lated genes, cyclin D1 and uPA, was suppressed by TSA
suggesting the strong anti-tumor activities of TSA.
HDAC inhibitors have more profound effect on the
growth of tumor cells than the normal cells [50]. Tumor
cells have increased levels of OPN, c-jun, cyclin D1 and
uPA. Our results revealed that the expression levels of
OPN, c-Jun and c-Fos are higher in SiHa as compared
to HeLa cells. This might be due to the fact that SiHa
cells are more invasive than HeLa cells. All these onco-
genic molecules have been shown to play important role
in regulation of tumor growth, proliferation and metas-
tasis. Therefore, it may be hypothesized that the growth
inhibitory activities of TSA might be due to the down
regulation of OPN, c-jun, cyclin D1 and uPA in both
HeLa and SiHa cells.
In summary, this is the first time we report that TSA
suppresses the PMA-induced transcription of OPN in
cervical cancer model. Thus, this evidence suggested that
the transcription factor, AP-1 has the binding ability to
the OPN regulatory region that ultimately regulates the
expression of OPN gene, which leads to tumor progres-
sion in cervical cancer (Figure 7D). Thus, inhibiting OPN
expression at the transcriptional level by TSA might pro-
vide a novel strategy for the prevention of cervical cancer.
Conclusions
This study has investigated the effects of HDAC inhibi-
tor, TSA on OPN transcription and characterized the
transcription factor binding site in the OPN promoter
that plays an important role in this phenomenon. The
data revealed that TSA suppresses the PMA-induced
OPN gene expression in a dose dependent manner and
induction of OPN transcription by PMA is mediated via
AP-1 transcription factor that forms a heterodimer of
c-jun and c-fos at the OPN promoter. The results also
indicated that TSA suppressed the PMA-induced c-Jun
recruitment to the OPN promoter by inhibiting c-Jun
expression. The PMA-induced hyperacetylation of his-
tones H3 and H4 associated with OPN promoter is also
inhibited by TSA. Moreover, PMA promoted cervical
tumor growth was significantly reduced by TSA in mice
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xenograft model. All these results highlight the mechan-
ism of action of TSA and suggest that the growth inhibi-
tory and anti-tumor activities of TSA might be exhibited,
in part, by downregulation of OPN expression. Further-
more, this study represents OPN as possible candidate
for anticancer therapies and blocking OPN expression at
transcriptional level by TSA might provide a new strategy
for management of cervical cancer.
Additional material
Additional file 1: TSA inhibits OPN transcription in SiHa cells. A. SiHa
cells were treated with 0-1 μM TSA for 6 h. Whole cell lysates were
analyzed by western blot using anti-OPN antibody. B. SiHa cells were
incubated with TSA under similar conditions as described above. Total
RNA was isolated and the levels of OPN mRNA were detected by
semiquantitative RT-PCR and analyzed by agarose gel electrophoresis.
Actin was used as control.
Additional file 2: Schematic representation of a proximal segment
of human OPN promoter and its sequence showing various
transcription factor binding sites.
Additional file 3: TSA suppresses c-Jun but not c-Fos expression in
SiHa cells. A and C. SiHa cells were treated with TSA (0-2 μM) for 3 h.
Cell lysates (50 μg) containing equal amount of total proteins were
analyzed by western blot using either anti-c-Jun or anti-c-Fos antibody.
B and D. SiHa cells were incubated with TSA under similar conditions as
described above. Total RNA was isolated and the levels of c-jun and c-fos
mRNAs were detected by semiquantitative RT-PCR. Actin was used as
control.
Additional file 4: TSA suppresses PMA-promoted cervical tumor
growth in mice xenograft model. A. The tumors were generated by
injecting HeLa cells subcutaneously into the flanks of female NOD/SCID
mice. Either PMA alone or in combination with two doses of TSA was
injected intratumorally. The tumors were excised and typical tumor
photographs are shown. B. Tumor samples were analyzed by
histopathology and immunofluorescence using anti-OPN, anti-c-Jun, anti-
cyclin D1 and anti-uPA antibodies and stained with Cy3-conjugated IgG.
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